Thursday, October 29, 2026, 1 PM-2 PM ET
Hear an expert discuss the evolving role of PD-L1 testing in HNSCC and ovarian cancer.
Webinar presenter Georgios Deftereos, MD, Professor of Pathology, Associate Director of the Clinical Cancer Genomics Laboratory, Director of Molecular Cytopathology, University of California, San Francisco
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Agilent.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 3, 2026, 1 PM-2 PM ET
Hear an expert discuss the challenges of detecting NRG1 fusions and how RNA-based testing can support more comprehensive fusion identification in clinical practice.
Webinar presenter Benjamin Weinberg, MD, Associate Professor of Medicine and Attending Physician
specializing in gastrointestinal medical oncology
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Diaceutics.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 10, 2026, 1 PM-2 PM ET
Join us for a session to help improve diagnostic accuracy in your practice when scoring HER2 IHC 0 with faint, incomplete membrane staining in ≤10% of tumor cells vs IHC 0 with no membrane staining detected in patients with mBC.
Webinar presenter Jeffrey Gregg, MD, University of Nevada
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Monday, November 16, 2026, 12:30 PM-2 PM ET
Hear experts discuss a multidisciplinary approach to oncopathology for HER2
assessments for solid tumors in the absence of a companion diagnostic.
Webinar presenters Funda Meric-Bernstam, MD, Chair, Department of Investigational Cancer Therapeutics Medical Director, Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Emina E. Torlakovic, MD, PhD, College of Medicine, University of Saskatchewan, Canadian Biomarker Quality Assurance, Saskatoon, Saskatchewan, Canada, and Carol Cheung, MD, PhD, JD, FRCPC, Deputy Director, Canadian Biomarker Quality, Assurance—Programme canadien d’assurance de la qualité des biomarqueurs
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
September 2016—Mopec introduced its Autopsy Saw 5000, which weighs less than three pounds and oscillates at 13,200 cycles per minute. Placement of the motor in the head and handle of the unit provides a balanced weight, resulting in a more precise cut with less operator fatigue, according to a company statement.
September 2016—Mayo Clinic has launched a new type of blood test that will be used to predict adverse cardiovascular events in patients with progressing coronary artery disease. The test measures blood concentrations of plasma ceramides, a class of lipids that are highly linked to cardiovascular disease processes. Researchers say this test is especially useful for patients with CAD when it does not improve with treatment or for young patients with premature CAD.
September 2016—Immuno Concepts announced that its Image Navigator automated microscope received 510(k) clearance. Image Navigator is a software program that controls a high-quality LED fluorescent microscope with a motorized stage to simplify and organize indirect fluorescent antibody testing.
September 2016—Oxford Gene Technology has expanded its catalog of fluorescence in situ hybridization products with nine Cytocell Aquarius probes: ETV6 Proximal Probe Green, ETV6 Distal Probe Red, MPO Probe Red, TP53 Probe Green, NUP214 Probe Red, DEK Probe Green, TAS2R1 (5p15.31) Probe Green, Chromosome 9 Satellite III Probe Aqua, and Chromosome 15 Alpha Satellite Probe Red.
September 2016—Genomic Health and Epic Sciences announced an exclusive agreement to commercialize Epic Sciences’ novel AR-V7 liquid biopsy test in the U.S. through Genomic Health’s commercial channel. The blood-based test detects the V7 variant of the androgen receptor protein in the nucleus of circulating tumor cells—information that can help guide treatment selection in patients with metastatic castration-resistant prostate cancer.
September 2016—Great Basin Scientific announced that its Shiga Toxin Direct Test received CE marking under the European directive on in vitro diagnostic medical devices. The test is now qualified for distribution in more than 32 countries across Europe.
September 2016—Qiagen launched a liquid biopsy workflow for clinical cancer research using its GeneReader NGS System for next-generation sequencing. The Actionable Insights Tumor Panel is a sample-to-insight solution for noninvasive liquid biopsies and formalin-fixed, paraffin-embedded tissue samples.
September 2016—SciGene introduced its CytoZyme HC Stabilized Pepsin, a high-potency solution used for digesting any tissue for FISH assays. Purified liquid CytoZyme HC provides consistent activity for more than 12 months at 4°C.
September 2016—The CellAsic Onix2 Microfluidic System for live cell imaging aims to give researchers precise environmental control over live cells. The small control system fits next to the microscope and the low-profile manifold and plate sit on top of the microscope stage, delivering precise control of gas, temperature, media changes, and more.
September 2016—Helmer Scientific released its MLR102 medical-grade countertop refrigerator with AdvanceCore cooling technology. The refrigerator is used to safeguard expensive, life-saving vaccines and medications as well as sensitive, and at times irreplaceable, reagents and patient samples.
